Tempus AI Inc (NASDAQ: TEM) - AI-Powered Precision Medicine Leader

Company Overview

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Founded in 2015 by Eric Lefkofsky in Chicago, Illinois, it was formerly known as Tempus Labs, Inc. before changing its name to Tempus AI, Inc. in January 2023. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM".

Business Model and Products

Tempus operates with one of the world's largest libraries of clinical and molecular data, coupled with an operating system designed to make this data accessible and useful. This enables physicians to make near real-time, data-driven decisions to deliver personalized patient care. The company's database now contains over 350 petabytes of clinical and molecular data, with connections to more than 40 million patient records.

Core Technology Platform

- Data Repository: Houses over 350 petabytes of clinical and molecular data linked to more than 40 million patient records.

- Operating System: Provides accessibility and utility for the data, facilitating data-driven medical decisions.

Key Products and Services

Genomics Division:

- Next-generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing offered to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.

- Algos, a suite of algorithmic tests specifically designed for oncology.

Data and Analytics:

- Insights: A licensed library of de-identified linked clinical, molecular, and imaging data, along with a suite of analytical services and cloud-and-compute tools for pharmaceutical and biotechnology companies.

- Trials: Provides clinical trial matching services for pharmaceutical companies.

- Lens: A platform for researchers and scientists to discover, access, and analyze Tempus data.

Digital Platforms:

- Hub: A desktop and mobile platform for ordering, managing, and receiving test results.

Financial Performance and Guidance

Q2 2025 Results (as of June 30, 2025)

- Revenue: Increased 89.6% year-over-year to $314.6 million.

- Genomics Revenue: Grew 115.3% year-over-year to $241.8 million, driven by accelerating volume growth in Oncology (26%) and Hereditary (32%) testing.

- Data and Services Revenue: Increased 35.7% year-over-year to $72.8 million.

- Gross Profit: Reached $195.0 million, a 158.3% year-over-year increase.

2024 Financial Highlights

- Annual Revenue: $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million.

- Market Capitalization: $15 billion (as of September 2025).

2025 Guidance

The company raised its full-year 2025 revenue guidance to $1.26 billion and expects positive adjusted EBITDA of $5 million, marking a significant improvement of $110 million over 2024.

Recent Strategic Developments

Major Acquisitions

- Paige Acquisition: Tempus announced the acquisition of Paige, an AI-focused digital pathology company, for $81.25 million, primarily paid in Tempus common stock. This acquisition includes Paige's dataset of nearly 7 million digitized pathology slides from 45 countries.

- Ambry Genetics: Acquisition closed on February 3, 2025.

FDA Approvals and Regulatory Milestones

- Received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform.

- Received U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device on September 22, 2025.

Strategic Partnerships

- Strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology.

- Expanded and extended strategic collaboration with Personalis, Inc. through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test.

Market Position and Focus Areas

Tempus leverages data and artificial intelligence to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company's primary focus areas are:

- Oncology Testing: Comprehensive cancer diagnostics and personalized treatment recommendations.

- Hereditary Testing: Genetic screening and analysis services.

- Data Analytics: Leveraging clinical and molecular data for research and drug development.

- AI-Powered Diagnostics: Advanced algorithmic testing platforms.

Investment Highlights

- Strong revenue growth trajectory with 89.6% year-over-year growth in Q2 2025.

- Approaching EBITDA profitability with expected positive adjusted EBITDA of $5 million in 2025.

- Possesses one of the largest healthcare data repositories globally with over 350 petabytes of data.

- Strategically positioned at the intersection of AI and precision medicine.

- Recent FDA approvals expanding its product portfolio.

- Strong partnerships with leading pharmaceutical companies.

Tempus AI represents a leading player in the AI-driven healthcare sector, combining extensive data assets with advanced artificial intelligence capabilities to transform precision medicine and improve patient outcomes across multiple therapeutic areas.